Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-666,842
Closed -$9.8M 10679
2025
Q3
$9.8M Buy
666,842
+317,397
+91% +$3.24M ﹤0.01% 3310
2025
Q2
$3.43M Buy
349,445
+146,238
+72% +$1.21M ﹤0.01% 4261
2025
Q1
$1.48M Buy
203,207
+90,022
+80% +$787K ﹤0.01% 4953
2024
Q4
$885K Sell
113,185
-128,319
-53% -$1.06M ﹤0.01% 5403
2024
Q3
$1.79M Buy
241,504
+115,448
+92% +$971K ﹤0.01% 4110
2024
Q2
$1.01M Sell
126,056
-194,676
-61% -$1.74M ﹤0.01% 4417
2024
Q1
$3.73M Buy
320,732
+36,235
+13% +$401K ﹤0.01% 3285
2023
Q4
$3.18M Buy
284,497
+183,515
+182% +$1.69M ﹤0.01% 3297
2023
Q3
$1.56M Sell
100,982
-22,836
-18% -$383K ﹤0.01% 3694
2023
Q2
$2.35M Sell
123,818
-17,306
-12% -$304K ﹤0.01% 3373
2023
Q1
$2.15M Buy
141,124
+131,005
+1,295% +$1.71M ﹤0.01% 3350
2022
Q4
$129K Sell
10,119
-70,462
-87% -$634K ﹤0.01% 5868
2022
Q3
$467K Sell
80,581
-9,780
-11% -$43K ﹤0.01% 4396
2022
Q2
$291K Buy
90,361
+64,096
+244% +$194K ﹤0.01% 4647
2022
Q1
$99K Buy
26,265
+18,989
+261% +$122K ﹤0.01% 5924
2021
Q4
$95K Buy
7,276
+2,921
+67% +$46.2K ﹤0.01% 6357
2021
Q3
$86K Sell
4,355
-3,157
-42% -$57.7K ﹤0.01% 5928
2021
Q2
$140K Buy
7,512
+573
+8% +$12.8K ﹤0.01% 5618
2021
Q1
$164K Buy
6,939
+316
+5% +$7.29K ﹤0.01% 5610
2020
Q4
$162K Buy
6,623
+3,646
+122% +$93.2K ﹤0.01% 5369
2020
Q3
$76K Sell
2,977
-1,423
-32% -$45.1K ﹤0.01% 5344
2020
Q2
$88K Sell
4,400
-287
-6% -$6.97K ﹤0.01% 5400
2020
Q1
$118K Sell
4,687
-1,506
-24% -$44K ﹤0.01% 5141
2019
Q4
$163K Buy
+6,193
New +$172K ﹤0.01% 5731

Other funds holding ETNB

UBS Group's ETNB Position: Q4 2025 in Review

UBS Group sold out of 89bio (ETNB) in Q4 2025, closing a stake of 666,842 shares — an estimated $9.8M sold.

UBS Group first reported a position in ETNB in Q4 2019 and held it in 24 quarters. The position peaked at $9.8M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • UBS Group reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 666,842 89bio shares in Q4 2025, an estimated $9.8M.
  • UBS Group first reported a position in 89bio in Q4 2019 and held it in 24 quarters.
  • UBS Group's 89bio position peaked at $9.8M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.